Positions for Amicus Therapeutics Inc (NASDAQ:FOLD)

“Big money sentiment for Amicus Therapeutics Inc (NASDAQ:FOLD) in Q3 2018 decreased to 1.26, SEC.gov filings reveal. So its down -0.04, from 2018Q2’s 1.3. 91 funds increased or started new equity positions, while 72 cut down and sold holdings in Amicus Therapeutics Inc so the sentiment is negative. These funds own 216.16 million shares, that’s down from 216.23 million shares in 2018Q2. Funds holding Amicus Therapeutics Inc in top 10 decreased from 6 to 5 for a decrease of 1. 25 Investors Sold All; 47 Reduced Holdings; 58 increased stakes while 33 funds bought stakes.

Most Amicus Therapeutics Inc Shareholders

As of Q3 2018 Perceptive Advisors Llc has 6.69% invested in Amicus Therapeutics Inc. Amicus Therapeutics Inc’s shareholder Sectoral Asset Management Inc owns 4.87 million shares as of Q3 2018. Venbio Select Advisor Llc reported 9.33 million shares. Redmile Group Llc revealed 8.40 million shares position in Amicus Therapeutics Inc. The Israel-based fund Sphera Funds Management Ltd. looks positive on Amicus Therapeutics Inc, possessing 1.79 million shares.

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases.The firm is valued at $2.69 billion. The Company’s principal product is the migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which has completed two global Phase III registration studies.Last it reported negative earnings. The firm is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; and AT3375 to treat Parkinson's disease.

FOLD hit $12.35 during the last trading session after $0.09 change.Currently Amicus Therapeutics, Inc. is downtrending after 17.72% change in last February 26, 2018. FOLD has also 1.68M shares volume. FOLD underperformed by 17.72% the S&P 500.

Earnings report for Amicus Therapeutics, Inc. (NASDAQ:FOLD) is awaited on February, 27., according to Zacks. Last year’s EPS was $-0.41, while now analysts expect change of 31.71 % up from current $-0.28 EPS. After $-0.31 EPS report previous quarter, Wall Street now sees -9.68 % EPS growth of Amicus Therapeutics, Inc..

Invesco holds 5.62M shs. Fosun Intl Limited reported 0.24% of its capital in Amicus Therapeutics, Inc. (NASDAQ:FOLD). 1.00M are owned by Rock Springs Capital Management Limited Partnership. Ardsley Advisory Prtnrs holds 0.83% or 510,000 shs. Voya Invest Mgmt Ltd Liability Corp owns 1.70 million shs. Principal Finance Gru reported 159,501 shs stake. Mcf Advisors Ltd Limited Liability Company holds 317 shs or 0% of its capital. 1.22 million were reported by Axa. Royal Comml Bank Of Canada holds 0% or 439,300 shs in its capital. Smith Asset Gp Lp owns 21,860 shs. Tudor Inv Corporation Et Al stated it has 36,597 shs or 0.01% of all its holdings. The Georgia-based Synovus Fincl has invested 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Moors And Cabot owns 16,550 shs. Manufacturers Life Insurance Company The reported 122,415 shs. Moreover, Canada Pension Plan Inv Board has 0.01% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 266,600 shs.

Amicus Therapeutics, Inc. registered $5.79 million net activity with 4 insider buys and 5 selling transactions since September 12, 2018. Shares for $626,500 were bought by PERCEPTIVE ADVISORS LLC on Friday, September 21. Campbell Bradley L also sold $425,135 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) shs. Baird William D III had sold 10,000 shs worth $122,275. $641,061 worth of stock was sold by Do Hung on Tuesday, January 15.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Ratings Coverage

In total 3 analysts cover Amicus Therapeutics (NASDAQ:FOLD). “Buy” rating has 3, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 4 are the (NASDAQ:FOLD)’s analyst reports since October 29, 2018 according to StockzIntelligence Inc. The stock rating was upgraded by Citigroup to “Buy” on Thursday, January 17.

For more Amicus Therapeutics, Inc. (NASDAQ:FOLD) news published recently go to: Nasdaq.com, Nasdaq.com, Globenewswire.com, Nasdaq.com or Nasdaq.com. The titles are as follows: “Health Care Sector Update for 02/25/2019: FOLD,ONCE,CRSP,AKCA,IONS,NVS – Nasdaq” published on February 25, 2019, “Why Amazon Won’t Buy FedEx – Nasdaq” on February 04, 2019, “Amicus Therapeutics to Announce Full-Year 2018 Financial Results on February 28, 2019 – GlobeNewswire” with a publish date: February 12, 2019, “Estée Lauder raises full-year forecast, shares rise – Nasdaq” and the last “Yelp Earnings: YELP Stock Soars After Crushing Q4 Earnings – Nasdaq” with publication date: February 13, 2019.